ArticleBlood advances2025

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.

Emma L Boertjes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.